Top

Published in:

01-11-2020 | Epstein-Barr Virus | Review Article

Epstein–Barr virus-associated gastric cancer: disease that requires special approach

Authors: Ekaterina Ignatova, Daria Seriak, Mikhail Fedyanin, Alexey Tryakin, Ilya Pokataev, Sofia Menshikova, Yuliya Vakhabova, Ksenia Smirnova, Sergey Tjulandin, Jaffer A. Ajani

Published in: Gastric Cancer | Issue 6/2020

Abstract

Epstein–Barr virus-associated gastric cancer [EBV-associated GC, EBV( +) GC] is a distinct molecular subtype of gastrointestinal (GI) cancers. It accounts for up to 10% of all molecular subtypes of gastric cancer (GC). It has unique genetic and epigenetic features, which determine its definitive phenotype with male and younger age predominance, proximal stomach localization, and diffuse adenocarcinoma histology. EBV( +) GC also has a unique epigenetic profile and mutational status with frequent mutations of PIK3CA, ARID1A and BCOR, and PD-L1 and PD-L2 amplifications, as well. The aim of this review is to highlight clinical significance of EBV( +) GC and prognostic role of EBV infection, and to determine potentially appropriate drug therapy for this disease.

Naseem M, Barzi A1, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15–22.CrossRef

Akiba S, Koriyama C, Herrera-Goepfert R, Eizuru Y. Epstein-Barr virus associated gastric carcinoma: epidemiological and clinicopathological features. Cancer Sci. 2008;99:195–201. https://doi.org/10.1111/j.1349-7006.2007.00674.x.CrossRefPubMed

Hinoue T, Bass AJ, Laird PW. Comparative molecular analysis of gastrointestinal comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell. 2018;33(4):721–735.e8. https://doi.org/10.1016/j.ccell.2018.03.010.CrossRefPubMedPubMedCentral

Bass A, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. https://doi.org/10.1038/nature13480.CrossRefPubMedCentral

Lee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009;24:354–65.CrossRef

Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int. 2010;60:337–50. https://doi.org/10.1111/j.1440-1827.2010.02533.x.CrossRefPubMed

Yanai H, Nishikawa J, Mizugaki Y, Shimizu N, Takada K, Matsusaki K, Toda T, Matsumoto Y, Tada M, Okita K. Endoscopic and pathologic features of Epstein-Barr virus-associated gastric carcinoma. Gastrointest Endosc. 1997;45:236–42. https://doi.org/10.1016/S0016-5107(97)70265-7].CrossRefPubMed

Nishikawa J, Yanai H, Mizugaki Y, Takada K, Tada M, Okita K. Case report: hypoechoic submucosal nodules: a sign of Epstein-Barr virus-associated early gastric cancer. J Gastroenterol Hepatol. 1998;13:585–90. https://doi.org/10.1111/j.1440-1746.1998.tb00694.x.CrossRefPubMed

Park JH, Kim EK, Kim YH, et al. Epstein-Bar virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer. 2016;19:1041–51.CrossRef

10.

Lee JY, Kim KM, Min BH, Lee JH, Rhee PL, Kim JJ. Epstein-Barr virus-associated lymphoepithelioma-like early gastric carcinomas and endoscopic submucosal dissection: case series. World J Gastroenterol. 2014;20:1365–70.CrossRef

11.

Yanai H, Chihara D, Harano M, Sakaguchi E, Murakami T, Nishikawa J. Epstein-Barr Virus-associated early gastric cancer treated with endoscopic submucosal dissection: a possible candidate for extended criteria of endoscopic submucosal dissection. Intern Med. 2019;58(22):3247–50. https://doi.org/10.2169/internalmedicine.3055-19.CrossRefPubMedPubMedCentral

12.

Koh J, Ock CY, Kim JW, Nam SK, Kwak Y, Yun S, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget. 2017;8(16):26356–67. https://doi.org/10.18632/oncotarget.15465.CrossRefPubMedPubMedCentral

13.

Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, Rabkin CS, Bass AJ. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925–322. https://doi.org/10.18632/oncotarget.9076.CrossRefPubMedPubMedCentral

14.

Spear PG, Longnecker R. Herpesvirus entry: an update. J Virol. 2003;77(19):10179–85. https://doi.org/10.1128/jvi.77.19.10179-10185.2003.CrossRefPubMedPubMedCentral

15.

Chesnokova LS, Hutt-Fletcher LM. Epstein-Barr virus infection mechanisms. Chin J Cancer. 2014;33(11):545–8. https://doi.org/10.5732/cjc.014.10168(Epub 2014 Oct 17).CrossRefPubMedPubMedCentral

16.

Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, Uozaki H, Seto Y, Takada K, Aburatani H, Fukayama M. Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res. 2011;71:7187–97.CrossRef

17.

Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, Takizawa T, Koike M, Mizutani S, Miyaki M, Hirai K. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach. Lab Invest. 1994;71:73–81.PubMed

18.

Frappier L. Contributions of Epstein-Barr nuclear antigen 1 (EBNA1) to cell immortalization and survival. Viruses. 2012;4(9):1537–47. https://doi.org/10.3390/v4091537(Epub 2012 Sep 13).CrossRefPubMedPubMedCentral

19.

Chen C, Li D, Guo N. Regulation of cellular and viral protein expression by the Epstein-Barr virus transcriptional regulator Zta: implications for therapy of EBV associated tumors. Cancer Biol Ther. 2009;8(11):987–95. https://doi.org/10.4161/cbt.8.11.8369.CrossRefPubMed

20.

Kang GH, Lee S, Kim WH, Lee HW, Kim JC, Rhyu M, et al. Demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol. 2002;160(3):787–94.CrossRef

21.

Matsusaka K, Funata S, Fukuyo M, Seto Y, Aburatani H, Fukayama M, Kaneda A. Epstein-Barr virus infection induces genome-wide de novo DNA methylation in non-neoplastic gastric epithelial cells. J Pathol. 2017;242:391–9. https://doi.org/10.1002/path.4909.CrossRefPubMed

22.

Fernandez AF, Rosales C, Lopez-Nieva P, Graña O, Ballestar E, Ropero S, et al. The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res. 2009;19(3):438–51. https://doi.org/10.1101/gr.083550.108(Epub 2009 Feb 10).CrossRefPubMedPubMedCentral

23.

Hino R, Uozaki H, Murakami N, Ushiku T, Shinozaki A, Ishikawa S, et al. Activation of DNA methyltransferase 1 by EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN gene in gastric carcinoma. Cancer Res. 2009;69(7):2766–74. https://doi.org/10.1158/0008-5472.CAN-08-3070.CrossRefPubMed

24.

Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421–34.CrossRef

25.

Shinozaki-Ushiku A, Kunita A, Isogai M, Hibiya T, Ushiku T, Takada K, Fukayama M. Profiling of virus-encoded microRNAs in Epstein-Barr virus-associated gastric carcinoma and their roles in gastric carcinogenesis. J Virol. 2015;89(10):5581–91. https://doi.org/10.1128/JVI.03639-14(Epub 2015 Mar 4).CrossRefPubMedPubMedCentral

26.

Shinozaki A, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. Cancer Res. 2010;70:4719–27.CrossRef

27.

Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L, et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-β/Smad pathway. PLoS ONE. 2012;7(12):e52465. https://doi.org/10.1371/journal.pone.0052465.CrossRefPubMedPubMedCentral

28.

Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21–41. https://doi.org/10.1007/82_2010_68.CrossRefPubMedPubMedCentral

29.

Yuen JW, Chung GT, Lun SW, Cheung CC, To KF, Lo KW. Epigenetic inactivation of inositol polyphosphate 4-phosphatase B (INPP4B), a regulator of PI3K/AKT signaling pathway in EBV-associated nasopharyngeal carcinoma. PLoS ONE. 2014;9(8):e105163. https://doi.org/10.1371/journal.pone.0105163.CrossRefPubMedPubMedCentral

30.

Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935–43. https://doi.org/10.1200/JCO.2012.48.3552(Epub 2013 Sep 16).CrossRefPubMedPubMedCentral

31.

Al-Batran SE, Riera-Knorrenschild J, Pauligk C, Goetze TO, Hegewisch-Becker S, Seraphin J, et al. A randomized, double-blind, multicenter phase III study evaluating paclitaxel with and without RAD001 in patients with gastric cancer who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC). J Clin Oncol. 2017;35(4_suppl):4–4.CrossRef

32.

Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: a SWOG cooperative group trial (S1005). Cancer. 2015;121(13):2193–7. https://doi.org/10.1002/cncr.29363(Epub 2015 Mar 30).CrossRefPubMedPubMedCentral

33.

Wang K, Law S, Wang K, Kan J, Yuen ST, Shi ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–23.CrossRef

34.

Day L, Chau CM, Nebozhyn M, Rennekamp AJ, Showe M, Lieberman PM. Chromatin profiling of Epstein-Barr virus latency control region. J Virol. 2007;81(12):6389–401. https://doi.org/10.1128/JVI.02172-06(Epub 2007 Apr 4).CrossRefPubMedPubMedCentral

35.

Grossmann V, Tiacci E, Holmes AB, Kohlmann A, Martelli MP, Kern W, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011;118(23):6153–63. https://doi.org/10.1182/blood-2011-07-365320(Epub 2011 Oct 19).CrossRefPubMed

36.

Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–21.CrossRef

37.

Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol. 2008;20(2):228–33. https://doi.org/10.1016/j.coi.2008.03.010(Epub 2008 May 12).CrossRefPubMedPubMedCentral

38.

Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–46. https://doi.org/10.1038/nrc3818.CrossRefPubMed

39.

Jackson CB, Giraud AS, Bp S, Kh W, Jackson CB, Giraud AS. STAT3 as a prognostic marker in human gastric cancer. J Gastroenterol Hepatol. 2009;24(4):646–51. https://doi.org/10.1111/j.1440-1746.2008.05671.x(Epub 2008 Nov 3).CrossRef

40.

Han J, Zhang K, Chen X, Jiang H, Kong Q. Expression of seven gastric cancer-associated genes and its relevance for Wnt, NF-k B and Stat3 signaling. APMIS. 2007;115(12):1331–433. https://doi.org/10.1111/j.1600-0643.2007.00695.x.CrossRefPubMed

41.

Sonbol MB, Bekaii-Saab T. A clinical trial protocol paper discussing the BRIGHTER study. Future Oncol. 2018;14:901–6.CrossRef

42.

Geddert H, Zur Hausen A, Gabbert HE, Sarbia M. EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol (Amst). 2010;33(3):143–9. https://doi.org/10.3233/ACP-CLO-2010-0540.CrossRef

43.

Chang M, Uozaki H, Chong J, Ushiku T, Sakuma K, Ishikawa S, et al. Human cancer biology CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res. 2006;12(10):2995–3002.CrossRef

44.

dos Jácome AAA, de Lima EM, Kazzi AI, Chaves GF, de Mendonça DC, Maciel MM, de Santos JS. Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease? Rev Soc Bras Med Trop. 2016;49(2):150–7. https://doi.org/10.1590/0037-8682-0270-2015.CrossRefPubMed

45.

Li Y, Liang Z, Tian Y, Cai W, Weng Z, Chen L, Zhang H, Bao Y, Zheng H, Zeng S, Bei C, Li Y, et al. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2. Cancer Sci. 2018;109(8):2435–45.CrossRef

46.

Dong H, Strome S, Salomao D, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800. https://doi.org/10.1038/nm730.CrossRefPubMed

47.

Pereira MA, Ramos MF, Faraj SF, et al. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol. 2018;117:829–39. https://doi.org/10.1002/jso.25022.CrossRefPubMed

48.

Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–73. https://doi.org/10.1158/1078-0432.CCR-13-0855(Epub 2013 May 14).CrossRefPubMedPubMedCentral

49.

Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012;18(6):1611–8. https://doi.org/10.1158/1078-0432(CCR-11-1942. Epub 2012 Jan 23. Erratum in: Clin Cancer Res. 2012 Apr 1;18(7):2117).CrossRefPubMedPubMedCentral

50.

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24–33. https://doi.org/10.1016/j.molmed.2014.10.009(Epub 2014 Oct 30).CrossRefPubMed

51.

Chen XZ, Chen H, Castro FA, Hu JK, Brenner H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore). 2015;94(20):e792. https://doi.org/10.1097/MD.0000000000000792.CrossRef

52.

Tokunaga M, Land CE, Uemura Y, Tokudome T, Tanaka S, Sato E. Epstein-Barr virus in gastric carcinoma. Am J Pathol. 1993;143:1250–4.PubMedPubMedCentral

53.

Shukla SK, Prasad KN, Tripathi A, Singh A, Saxena A, Ghoshal UC, Krishnani N, Husain N. Epstein-Barr virus DNA load and its association with Helicobacter pylori infection in gastroduodenal diseases. Braz J Infect Dis. 2011;15(6):583–90.CrossRef

54.

Martínez-López JL, Torres J, Camorlinga-Ponce M, Mantilla A, Leal YA, Fuentes-Pananá EM. Evidence of Epstein-Barr virus association with gastric cancer and non-atrophic gastritis. Viruses. 2014;6(1):301–18. https://doi.org/10.3390/v6010301.CrossRefPubMedPubMedCentral

55.

Lee MA, Hong YS, Kang JH, Lee KS, You JY, Lee KY, Park CH. Detection of Epstein-Barr virus by PCR and expression of LMP1, p53, CD44 in gastric cancer. Korean J Intern Med. 2004;19(1):43–7. https://doi.org/10.3904/kjim.2004.19.1.43.CrossRefPubMedPubMedCentral

56.

Oda K, Koda K. Original article Detection of Epstein-Barr virus in gastric carcinoma cells and surrounding lymphocytes. Gastric Cancer. 2003;6(3):173–8.CrossRef

57.

Shukla S, Prasad K, Tripathi A, Ghoshal U, Krishnani N, Husain N. Expression profile of latent and lytic transcripts of epstein–barr virus in patients with gastroduodenal diseases: a study from northern India. J Med Virol. 2012;84(8):1289–97. https://doi.org/10.1002/jmv.23322.CrossRefPubMed

58.

Rowlands DC, Ito M, Mangham DC, Reynolds G, Herbst H, Hallissey MT, et al. Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas. Br J Cancer. 2016;114(12):e15. https://doi.org/10.1038/bjc.2016.156.CrossRefPubMedPubMedCentral

59.

Kim Y, Shin A, Gwack J, Ko KP, Kim CS, Park SK, Hong YC, Kang D, Yoo KY. Epstein-Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study. Br J Cancer. 2009;101(3):526–9. https://doi.org/10.1038/sj.bjc.6605146(Epub 2009 Jun 23).CrossRefPubMedPubMedCentral

60.

Koshiol J, Qiao Y, Kamangar F. Epstein-Barr virus serology and gastric cancer incidence and survival. Br J Cancer. 2007;97(11):1567–9 (Epub 2007 Nov 6).CrossRef

61.

Levine PH, Lennelte ET, Hildesheim A, Shibata D, Nomura A. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma. Int J Cancer. 1995;60(5):642–4.CrossRef

62.

Shinkura R, Yamamoto N, Koriyama C, Shinmura Y, Eizuru Y, Tokunaga M. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and-negative gastric carcinoma cases in Japan. J Med Virol. 2000;60(4):411–6.CrossRef

63.

Lo YMD, Chan WY, Ng EKW, Chan LYS, Lai PBS, Tam JS, et al. Circulating Epstein-Barr virus DNA in the serum of patients with gastric carcinoma. Clin Cancer Res. 2001;7(7):1856–9.PubMed

64.

Shoda K, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Kosuga T, Komatsu S, Shiozaki A, Okamoto K, Imoto I, Otsuji E. Clinical utility of circulating cell-free Epstein-Barr virus DNA in patients with gastric cancer. Oncotarget. 2017;8(17):28796–804. https://doi.org/10.18632/oncotarget.15675.CrossRefPubMedPubMedCentral

65.

Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res. 2017. https://doi.org/10.1158/1078-0432.CCR-16-2211(Epub ahead of print).CrossRefPubMedPubMedCentral

66.

Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236–43. https://doi.org/10.1136/gutjnl-2013-304531(Epub 2013 Apr 12).CrossRefPubMed

67.

Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;16(9):901–9. https://doi.org/10.2147/DDDT.S75152.CrossRef

68.

Muro K, Bang Y-J, Shankaran V, Geva R, Catenacci DVT, Gupta S, et al. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(3_suppl):3.CrossRef

69.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.CrossRef

70.

Tabernero J, Van Cutsem E, Bang Y.-J, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HRC, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol 2019:37(18). https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007.

71.

Bang YJ, Cho JY, Kim YH, et al. Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer. Clin Cancer Res. 2017;23(19):5671–8. https://doi.org/10.1158/1078-0432.CCR-17-0025(Epub 2017 Jun 27).CrossRefPubMed

72.

Bang YJ, Ruiz EY2, Van Cutsem E. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052–60.CrossRef

73.

Kim ST, Cristescu R, Bass AJ, Kim K, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–588. https://doi.org/10.1038/s41591-018-0101-z(Epub 2018 Jul 16).CrossRefPubMed

Title: Epstein–Barr virus-associated gastric cancer: disease that requires special approach
Authors: Ekaterina Ignatova
Daria Seriak
Mikhail Fedyanin
Alexey Tryakin
Ilya Pokataev
Sofia Menshikova
Yuliya Vakhabova
Ksenia Smirnova
Sergey Tjulandin
Jaffer A. Ajani
Publication date: 01-11-2020
Publisher: Springer Singapore
Keywords: Epstein-Barr Virus
Gastric Cancer
Gastric Cancer
Polymerase Chain Reaction
Published in: Gastric Cancer / Issue 6/2020
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI: https://doi.org/10.1007/s10120-020-01095-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab

LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A1

Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer

Clinical outcomes of laparoscopic and endoscopic cooperative surgery for submucosal tumors on the esophagogastric junction: a retrospective single-center analysis

Jab1 promotes gastric cancer tumorigenesis via non-ubiquitin proteasomal degradation of p14ARF

Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage